Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT01395316
First received: July 13, 2011
Last updated: January 23, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)